GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments.
The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners Healthcare and GC&H Investments. In addition, all of the A round investors, HealthCare Ventures, LLC, Morgenthaler Ventures and Sequel Venture Partners, also participated.
This brings the September total capital raised in Colorado to nearly $225 million (GlobeImmune, $34.3 million, Replidyne $62.5 million and Myogen $116.4 million). A very good sign indeed, though just scratching the surface of what is yet to come from the Rocky Mountain state.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment